Handling sirolimus in clinical practice. Spanish Nephrology Society.
Oppenheimer
F
F
Servicio de Nefrología, Hospital Clinic, Barcelona. oppenhei@medicina.ub.es
Alonso
A
A
Arias
M
M
Campistol
J M
JM
González Molina
M
M
González Posada
J M
JM
Grinyo
J M
JM
Morales
J M
JM
Sánchez Fructuoso
A
A
Sánchez-Plumed
J
J
Ruiz
J C
JC
D000014:Abnormalities, Drug-Induced; D000818:Animals; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D015337:Multicenter Studies as Topic; D016377:Organ Transplantation; D011183:Postoperative Complications / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D020123:Sirolimus